Template:Central line with coagulopathy: Difference between revisions

 
Line 1: Line 1:
===[[Procedures in patients with coagulopathies|Central line if coagulopathic]]===
===[[Procedures in patients with coagulopathies|Central line if coagulopathic]]===
*Preferentially use a compressible site such as the [[Central line: femoral|femoral]] location (avoid the [[Central line: internal jugular|IJ]] and [[Central line: subclavian|subclavian]] if possible)
*Preferentially use a compressible site such as the [[Central line: femoral|femoral]] location (avoid the [[Central line: internal jugular|IJ]] and [[Central line: subclavian|subclavian]] if possible, though IJ preferred over subclavian)
*No benefit to giving [[FFP]] unless artery is punctured<ref>Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit. Intens Care Med 1999; 25:5</ref>
*No benefit to giving [[FFP]] unless artery is punctured<ref>Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit. Intens Care Med 1999; 25:5</ref>
**However, consider giving [[FFP]] if patient has [[Hemophilia|hemophilia]]<ref>Morado M.et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7:551–556</ref>
**However, consider giving [[FFP]] if patient has [[Hemophilia|hemophilia]]<ref>Morado M.et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7:551–556</ref>

Latest revision as of 06:18, 6 January 2022

Central line if coagulopathic

  • Preferentially use a compressible site such as the femoral location (avoid the IJ and subclavian if possible, though IJ preferred over subclavian)
  • No benefit to giving FFP unless artery is punctured[1]
  1. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit. Intens Care Med 1999; 25:5
  2. Morado M.et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7:551–556